Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
US |
|
Ureru Net Advertising Group Co Ltd
TSE:9235
|
JP |
|
Propanc Biopharma Inc
NASDAQ:PPCB
|
AU |
|
L
|
Lam Dong Investment and Hydraulic Construction JSC
VN:LHC
|
VN |
|
Digital Brands Group Inc
OTC:DBGI
|
US |
|
K
|
KBI Dongkook Ind Co Ltd
KRX:001620
|
KR |
|
Exeo Entertainment Inc
OTC:EXEO
|
US |
|
S
|
Simmtech Holdings Co Ltd
KOSDAQ:036710
|
KR |
|
Dongwon F & B Co Ltd
KRX:049770
|
KR |
|
G
|
Guangzhou Rural Commercial Bank Co Ltd
HKEX:1551
|
CN |
|
K
|
Kosy JSC
VN:KOS
|
VN |
Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.
